SARS-antibody-80R-(IgG) |
|||
E24CHA001 | EnoGene | Human-,-Human-IgG1. | EUR 276.5 |
Description: Human, Human IgG1. |
Human IgG antibody Laboratories manufactures the recombinant protein sars-cov3 reagents distributed by Genprice. The Recombinant Protein Sars-Cov3 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Recombinant. Other Recombinant products are available in stock. Specificity: Recombinant Category: Protein Group: Sars-Cov3
True Blue |
||
TargetMol Chemicals | 5mg | Ask for price |
Description: True Blue |
True Blue |
||
MyBiosource | 5(mg | EUR 635 |
True Blue |
||
MyBiosource | 5x5(mg | EUR 2705 |
Human SARS-CoV-2 Spike Protein S1 IgG (S1-IgG) ELISA Kit |
||
Sunlong | 96 Tests | EUR 468 |
SARS-CoV-2 Human IgG Assay Control |
||
Genovis AB | 1 mL | EUR 105 |
Human SARS-CoV-2 Nucleocapsid Protein IgG ELISA Kit |
||
Abbexa | 100 µl | EUR 593.75 |
Human SARS-CoV-2 Spike Protein IgG ELISA Kit |
||
Abbexa | 100 µg | EUR 593.75 |
SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein |
|||
92-764 | ProSci | 0.05 mg | EUR 651.3 |
Description: The Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV) is an enveloped, positive-stranded RNA viruses that can cause a severe respiratory disease. Its genome consists of a ∼30 kb linear, non-segmented, capped, polycistronic, polyadenylated RNA molecule, the first two-third of which is directly translated into two large polyproteins. These two polypeptides are processed into 16 non-structural proteins (nsps), forming the replicase complex, which is active in the cytoplasm in close association with cellular membranes. Nsp1 was proved to be able to suppress host gene expression by promoting host mRNA degradation and was involved in cellular chemokine deregulation. This virus evades the host innate immune response in part through the expression of its non-structural protein (nsp) 1, which inhibits both host gene expression and virus- and interferon (IFN)-dependent signaling. Thus, nsp1 is a promising target for drugs, as inhibition of nsp1 would make SARS-CoV more susceptible to the host antiviral defenses. |
SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein |
|||
97-095 | ProSci | 0.1 mg | EUR 821.4 |
Description: The viral nonstructural protein 1 (nsP1) is the only membrane-associated protein that anchors the replication complex to the cellular membranes. NSP1 inhibits host translation by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome complex further induces an endonucleolytic cleavage near the 5'UTR of host mRNAs, targeting them for degradation. Viral mRNAs are not susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the presence of a 5'-end leader sequence and are therefore protected from degradation. By suppressing host gene expression, nsp1 facilitates efficient viral gene expression in infected cells and evasion from host immune response. |
SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein |
|||
97-096 | ProSci | 0.1 mg | EUR 821.4 |
Description: During the formation of the coronaviral replication/transcription complex, essential steps include processing of the conserved polyprotein nsp7-10 region by the main protease Mpro and subsequent complex formation of the released nsp's. Upon infecting host cells, coronaviruses assemble a multi-subunit RNA-synthesis complex of viral non-structural proteins (nsp) responsible for the replication and transcription of the viral genome. non-structural proteins 7 (NSP7) forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein |
|||
97-097 | ProSci | 0.1 mg | EUR 821.4 |
Description: NSP8, forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10) were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity. |
SARS-CoV-2 (COVID-19) NSP3 Recombinant Protein |
|||
10-406 | ProSci | 0.1 mg | EUR 651.3 |
Description: The coronaviral proteases, papain-like protease (PLpro) and 3C-like protease (3CLpro), are attractive antiviral drug targets because they are essential for coronaviral replication. PLpro has the additional function of stripping ubiquitin and ISG15 from host-cell proteins to aid coronaviruses in their evasion of the host innate immune responses. Targeting PLpro with antiviral drugs may have an advantage in not only inhibiting viral replication but also inhibiting the dysregulation of signaling cascades in infected cells that may lead to cell death in surrounding, uninfected cells. |
SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein |
|||
10-415 | ProSci | 0.1 mg | EUR 651.3 |
Description: Cleavage by the viral main protease, 3CLpro results in generating the nsp8 protein, The nsp8 protein has been shown to associate with several other nsps and to colocalize with these nsps in cytoplasmic complexes that are important for viral RNA synthesis. It forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. Nsp8 was shown to have RNA-dependent RNA polymerase (RdRp) activity that could be involved in producing primers utilized by nsp12 which is normally accepted to be the RdRp for SARS-CoV. |
SARS-CoV-2 (COVID-19) NSP1 Recombinant Protein |
|||
10-416 | ProSci | 0.1 mg | EUR 651.3 |
Description: The Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV) is an enveloped, positive-stranded RNA viruses that can cause a severe respiratory disease. Its genome consists of a ∼30 kb linear, non-segmented, capped, polycistronic, polyadenylated RNA molecule, the first two-third of which is directly translated into two large polyproteins. These two polypeptides are processed into 16 non-structural proteins (nsps), forming the replicase complex, which is active in the cytoplasm in close association with cellular membranes. Nsp1 was proved to be able to suppress host gene expression by promoting host mRNA degradation and was involved in cellular chemokine deregulation. This virus evades the host innate immune response in part through the expression of its non-structural protein (nsp) 1, which inhibits both host gene expression and virus- and interferon (IFN)-dependent signaling. Thus, nsp1 is a promising target for drugs, as inhibition of nsp1 would make SARS-CoV more susceptible to the host antiviral defenses. |
SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein |
|||
10-417 | ProSci | 0.1 mg | EUR 651.3 |
Description: May participate in viral replication by acting as a ssRNA-binding protein. |
SARS-CoV-2 (COVID-19) NSP2 Recombinant Protein |
|||
10-425 | ProSci | 0.1 mg | EUR 651.3 |
Description: The positive-stranded RNA genome of the coronaviruses is translated from ORF1 to yield polyproteins that are proteolytically processed into intermediate and mature nonstructural proteins (nsps). SARS-CoV 2 polyproteins incorporate 16 protein domains (nsps). The putative non-structural protein 2 (nsp2) of SARS-CoV plays an important role in viral transcription and replication, and is an attractive target for anti-SARS drug development. |
SARS-CoV-2 (COVID-19) ORF8 Recombinant protein |
|||
10-436 | ProSci | 0.1 mg | EUR 695.4 |
Description: May play a role in host-virus interaction. |
SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein |
|||
10-002 | ProSci | 0.1 mg | EUR 714.3 |
Description: LOCUS: QHD43422 121aa linear VRL 18-MAR-2020 |
SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
|||
20-187 | ProSci | 0.1 mg | EUR 726.9 |
Description: SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
|||
20-188 | ProSci | 0.1 mg | EUR 726.9 |
Description: SARS-CoV-2 (COVID-19) NSP5 Recombinant Protein |
SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein |
|||
20-192 | ProSci | 0.1 mg | EUR 726.9 |
Description: SARS-CoV-2 (COVID-19) ORF8 Recombinant Protein |
SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein |
|||
20-212 | ProSci | 0.1 mg | EUR 726.9 |
Description: SARS-CoV-2 (COVID-19) NSP9 Recombinant Protein |
SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein |
|||
20-213 | ProSci | 0.1 mg | EUR 726.9 |
Description: SARS-CoV-2 (COVID-19) NSP8 Recombinant Protein |
SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein |
|||
20-214 | ProSci | 0.1 mg | EUR 726.9 |
Description: SARS-CoV-2 (COVID-19) NSP7 Recombinant Protein |